

1 **Title page**

2

3

Acceptance of COVID 19 vaccine among sub-

4

Sahara African (SSA): a comparative study of

5

residents and diaspora dwellers

6

7

8

Chundung Asabe Miner^{1¶}, Chikasirimobi G. Timothy^{2¶}, Khathutshelo Percy

9

Mashige^{3¶}, Uchechukwu Levi Osuagwu^{4¶*}, Esther Awazzi Envuladu^{5&}, Onyekachukwu

10

Mary-Anne Amiebenomo^{6#a&}, Godwin Ovenseri-Ogbomo^{7&}, Deborah Donald Charwe^{8&},

11

Piwuna Christopher Goson^{9&}, Bernadine N Ekpenyong^{10&}, Emmanuel Kwasi Abu^{11&},

12

Raymond Langsi^{12&}, Richard Oloruntoba^{13&}, Tanko Ishaya^{14&}, , Kingsley Agho^{15¶}

13

14

¹Department of Community Medicine, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria

15

16

²Department of Optometry and Vision Sciences, School of Public Health, Biomedical Sciences and Technology, Masinde Muliro University of Science and Technology, Kakamega, Kenya

17

18

³African Vision Research Institute (AVRI), School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

19

20

⁴Translational Health Research Unit (THRI), School of Medicine, Western Sydney University, Campbelltown, Australia

21

22

⁵Department of Community Medicine, College of Health Sciences, University of Jos, Jos, Nigeria

23

24

⁶Department of Optometry, Faculty of Life Sciences, University of Benin, Ugbowo, Benin City, Nigeria

25

26

⁷Department of Optometry, Centre for Health Sciences, University of the Highlands and Islands, Inverness, UK

27

28

⁸Tanzania Food and Nutrition Center, Dar-es-Salaam, Tanzania

29

30

⁹Department of Psychiatry, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria

31

32

¹⁰Department of Public Health, Faculty of Allied Medical Sciences, College of Medical

33

Sciences, University of Calabar, Calabar, Cross River State, Nigeria

34

¹¹Department of Optometry and Vision Science, School of Allied Health Sciences, College of

35

Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana

36

¹²Health Division, University of Bamenda, Bambili, Cameroon

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 ¹³School of Management and Marketing, Curtin Business School, Curtin University, Bent-
38 ley, Australia

39 ¹⁴Department of Computer Science, University of Jos, Jos, Nigeria

40 ¹⁵School of Health Science, Western Sydney University, Campbelltown, Australia;

41 ^{#a} Current address: School of Optometry and Vision Sciences, College of Biomedical
42 Sciences, Cardiff University, Cardiff, United Kingdom

43

44 *Corresponding author:

45 Email: l.osuagwu@westernsydney.edu.au (ULO)

46

47 ¶ These authors contributed equally to this work

48 & These authors also contributed equally to this work

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64 **Abstract**

65

66 The COVID-19 vaccines are being rolled out across all the Sub-Saharan Africa (SSA)
67 countries, with countries setting targets for achieving full vaccination rates. The aim of this
68 study was to compare the uptake of, resistance and hesitancy to the COVID-19 vaccine between
69 SSA locally residents and in the diaspora. This was a cross-sectional study conducted using a
70 web and paper-based questionnaire to obtain relevant information on COVID-19 vaccine
71 acceptance. The survey items included questions on demography, uptake and planned
72 acceptance or non-acceptance of the COVID-19 vaccines among SSAs. Multinomial logistic
73 regression was used to determine probabilities of outcomes for factors associated with COVID-
74 19 vaccination resistance and hesitancy among SSA respondents residing within and outside
75 Africa. Uptake of COVID-19 vaccines varied among the local (14.2%) and diaspora (25.3%)
76 residents. There was more resistance to COVID-19 vaccine among locals (68.1%) and across
77 the sociodemographic variables of sex [adjusted Relative Risk (ARR) =0.73, 95% CI; 0.58 –
78 0.93], primary/less [ARR =0.22, 95% CI; 0.12 – 0.40] and bachelor’s degree [ARR =0.58, 95%
79 CI; 0.43 – 0.77] educational levels, occupation [ARR =0.32, 95% CI; 0.25 - 0.40] and working
80 status [ARR =1.40, 95%CI; 1.06 - 1.84]. COVID-19 vaccine hesitancy was almost similar
81 between locals and diasporas (17.7% and 17.8% respectively) significant only among
82 healthcare workers [ARR =0.46, 95% CI; 0.16 – 1.35] in the diaspora after adjusting for the
83 variables. Similarly, knowledge and perception of COVID-19 vaccine among locals were
84 substantial, but only perception was remarkable to resistance [ARR =0.86, 95% CI; 0.82 –
85 0.90] and hesitancy [ARR =0.85, 95% CI; 0.80 – 0.90] of the vaccine. Differences exist in the
86 factors that influence COVID-19 vaccine acceptance between local SSA residents and those in
87 the diaspora. Knowledge about COVID-19 vaccines affects the uptake, resistance, and
88 hesitancy to the COVID-19 vaccine. Information campaigns focusing on the efficacy and safety
89 of vaccines could lead to improved acceptance of COVID-19 vaccines.

90 **Keywords:** Vaccination; Acceptance; COVID-19; Hesitancy; Resistance; Sub-Sahara Africa;
91 Locals; Diaspora

92 **Running title:** COVID-19 vaccine uptake, resistance, hesitancy

93

94 **Introduction**

95

96 The coronavirus disease (COVID-19) pandemic that started in December of 2019,
97 initially reported in Wuhan, China, has continued despite preventative measures adopted
98 worldwide under the guidance of the World Health Organization (WHO). Many countries
99 have experienced their second, third and fourth waves in terms of cases and resultant
100 deaths.[1- 4] The outbreak of the new Omicron variant in different countries [5-7] is of global
101 concern,[8] as it threatens the return to normalcy and the ongoing COVID-19 vaccination
102 programmes. Non-pharmaceutical interventions to minimise the spread of infections included
103 travel restrictions, lockdowns, physical distancing, regular handwashing and wearing of face
104 masks.[9-10] From the onset of the pandemic, scientists and pharmaceutical companies began
105 the development of COVID-19 vaccines to offer protection against severe disease.[11]

106 The Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Johnson &Johnson,
107 Sinopharm/BIBP and India's Covishield,[12-13] vaccines are licensed for use across the
108 globe. The utilisation of any vaccine can be influenced by system, client and provider
109 factors,[14] but in particular, vaccine acceptance plays a huge role for clients and providers.
110 Generally, the acceptance of any vaccine has been shown to be influenced by demographic
111 factors, knowledge of the disease and the consequences of contracting it, perceptions of
112 susceptibility, potential benefits of a health action and the occurrence of one or more cues to
113 action.[11-17] Similar factors may influence COVID-19 vaccine acceptance.

114 The COVID-19 vaccines have shown to be efficient and safe,[18] however, their
115 acceptance is a major barrier to the successful rollout plans in different countries including
116 the SSA region. This is further exacerbated by the mistrust in the government demonstrated
117 by residents in this region.[19] The WHO defines vaccine hesitancy as a ‘delay in acceptance
118 or refusal of safe vaccines despite availability of vaccine services’[20] It is also stated to be
119 one of the top ten threats to global health.[21-22] Vaccine hesitancy is used to describe a
120 phenomenon where individuals are unsure of getting vaccinated. Those who object to getting
121 the vaccine are defined as vaccine resistant. [23]

122 The success of vaccines depends on achieving maximum coverage and thereby
123 attaining herd immunity.[24] Vaccine acceptance is therefore crucial to the efforts currently
124 made by public health experts of ensuring that the communities in every country are fully
125 vaccinated. Studies have shown that there have been disparities in vaccine acceptance for
126 other conditions, and factors such as age, race and ethnicity, social class, country and region
127 of origin were associated with acceptance of vaccines.[25-26] Similar results were reported
128 for COVID-19 vaccines.[27-28]

129 Persons in the diaspora are “national migrant communities living in interaction among
130 themselves and with their country of origin”.[29] Africans in the diaspora have been referred
131 to by the African Union as “people of African origin living outside of the continent,
132 irrespective of their citizenship and nationality, and who are willing to contribute to the
133 development of the continent and the building of the African Union”.[30] It is generally
134 believed that being in the diaspora provides Africans with greater opportunities to become
135 more enlightened and therefore adopt different approaches to decision making.[30]
136 Furthermore, studies have shown that there is geographical and spatial variation in the uptake
137 of vaccines.[31-32] In SSA, access to COVID-19 vaccines have improved, but the
138 availability of vaccines and uptake remains substantially low compared with the rich

139 European and North-American countries [33], and only 11% of the adult population in Africa
140 are fully vaccinated as at January 2021.[34] Although there are significant differences in the
141 vaccination programmes and their rollout between countries,[35-36] the fact that a previous
142 study found similarities in the attitude and risk perception towards COVID-19 among
143 Africans living locally and those in the diaspora (mostly living in Western countries) during
144 the lockdown, [37] suggests there could be similarities in their acceptance of the COVID-19
145 vaccination. This study, therefore, sought to investigate the differences in the acceptance of
146 COVID-19 vaccination of Sub-Sahara Africans living on the African continent and those in
147 the diaspora. Although different studies exist that looked at COVID-19 vaccine acceptance,
148 none had compared the same between locals and diaspora dwellers in SSA at the time of this
149 study.

150 **Methods**

151 **Ethics and consent**

152 Ethical approval to conduct the study was obtained from the Humanities and Social
153 Sciences Research Ethics Committee (approval #: HSSREC 00002504/2021) of the
154 University of KwaZulu-Natal, Durban, South Africa. The study adhered to the tenets of the
155 Declaration of Helsinki involving human participants [38], and anonymous voluntary
156 informed consent was obtained from all participants as part of the preamble accompanying
157 the questionnaire.

158 Participants were included in this study if they were of African origin, aged 18 years
159 and older, and provided consent. Completion of the questionnaire was only possible after the
160 participants had responded to the consent question, 'do you voluntarily take part in this
161 study?' Those who answered 'No' to this question were automatically locked out from the
162 survey platform.

163 **Study setting and population**

164 The study population included adults who were 18 years and older and were of sub-
165 Saharan Africans residing locally (in Africa) and in diaspora (outside of Africa). Respondents
166 from several countries in SSA, mostly from Cameroun, Ghana, Nigeria, South Africa,
167 Tanzania, and those in diaspora mostly living in Australia, United Kingdom, United States,
168 Saudi Arabia, Canada, China, and India took part in this study.

169 **Sample size determination**

170 The sample size was determined using Cochran's formulae ($n = z^2pq/d^2$) with the
171 assumption of a proportion of 50% at a confidence level of 95% with an error margin of
172 2.5%. A 20% non-response rate was assumed, and a minimum sample size of 2401 was
173 obtained.

174 **Study design**

175 This was a web-based cross-sectional survey carried out between 14th of March and
176 17th of May 2021. Due to the continued COVID-19 lockdowns in many of the target
177 countries at the time of this study, web-based study was most appropriate even though it may
178 have excluded some participants with no access to internet-based phone/computer services.

179 **The survey instrument and data collection**

180 Data was collected using a validated self-administered questionnaire adapted from a
181 previous study.[39] The survey tool was tested for the internal validity of the items, and
182 Cronbach's alpha coefficient score ranged from 0.70 and 0.74, indicating satisfactory
183 consistency.[40] The questionnaire was designed on survey monkey in both English and
184 French, which are spoken languages in 26 and 21 SSA countries, respectively.[41] The
185 questionnaire was disseminated electronically through an e-link on social media networks
186 such as WhatsApp, Facebook and e-mail. There was an accompanying introductory section

187 that included the background and goal of the study, procedure for participation and informed
188 consent guide. Participants were requested on the introductory page not to participate in the
189 survey more than once.

190 **Confounding variables**

191 The survey instrument showing the various variables collected has been presented in
192 the Supporting information (S1 Table). The independent variables included
193 sociodemographic variables; age, gender, region, marital status, the highest level of
194 education, occupation, employment status, religion, smoking status, previous vaccination for
195 other conditions and pre-existing medical conditions; knowledge of COVID-19 vaccines;
196 perception of risk for contracting COVID-19; and attitude towards vaccination for COVID-
197 19 (S1 Table). The exposure variable was the ‘place of residence’ (local or diaspora).

198 The COVID-19 vaccine knowledge items had 10 questions on a Likert scale with five
199 levels as indicated in SI Table 1. The scores for nine of the items ranged from 0 (lowest) to 4
200 (highest) while, for one item, it was coded as 1 for Yes and 0 for No. The overall knowledge
201 towards COVID-19 vaccination score ranged from 0 -37 points, with a higher knowledge
202 score indicating a better knowledge towards COVID-19 vaccination.

203 The attitude towards the COVID-19 vaccine items included four items with each
204 assigned 2 points for ‘yes’, 1 point for ‘unsure’ and 0 point for ‘No’. The total attitude score
205 ranged from 0 to 8, with a higher score denoting a better attitude towards COVID-19
206 vaccination.

207 The risk perception for contracting the disease after vaccination included questions on
208 how the participants rate their risk of becoming infected with the virus and risk of dying from
209 the infection. The responses were structured using a Likert scale with five levels (S1 Table),
210 with scores for each item ranging from 0 (lowest) to 4 (highest). The total perception score

211 ranged from 0 to 8, with a higher score representing a higher perception of contracting the
212 infection following COVID-19 vaccination.

213 **Main outcome variables**

214 The main outcomes were vaccine uptake, resistance and hesitancy. Uptake was
215 determined by answering ‘yes’ to the question “*Have you been vaccinated against COVID-*
216 *19?*”. The vaccine resistant group were those that answered ‘no’ to the question ‘*Will you be*
217 *willing to be vaccinated against COVID-19 if the vaccine becomes available in your*
218 *country?*’, while those who answered ‘not sure’ were defined as the vaccine ‘hesitant’ group.

219 **Data analysis**

220 Data were analyzed using STATA/MP version 14 (Stata Corp 2015, College Station,
221 TX, USA. A 95% confidence interval (CI) was set for this survey, and a p-value of <0.05 was
222 considered statistically significant. Descriptive data were summarized and presented in tables
223 and charts using frequencies, percentages, mean and standard deviations as required.
224 Multinomial logistic regression analyses were used to examine the COVID-19 vaccination
225 status on sources of information. As part of the multiple multinomial logistic regression
226 analyses, a staged modelling technique was carried out. Elimination method was conducted
227 using multiple multinomial logistic regression modelling techniques to remove statistically
228 non-significant variables. Demographic factors were first entered into the baseline multiple
229 regression model, followed by health indicators factors and the exposure variables were
230 examined in the final model, which also included knowledge, attitude and risk perception
231 variables, keeping only those variables significant in the previous model. In the final model,
232 we tested and reported any co-linearity. The relative risk with 95% confidence intervals were
233 calculated to assess the adjusted risks of independent variables.

234

235 Results

236 Characteristics of the respondents

237 There was a total of 2545 SSA respondents [2391 locals (93.9%) and 154 in the
238 diaspora (6.1%)]. Table 1 shows the frequency and percentage distribution of respondents
239 according to their socio-demographic variables. The majority of the SSA local residents
240 (67.8%) were younger than 38 years, while those in the diaspora were older. There were more
241 females than males in both groups, and the majority were originally from West Africa (locals
242 55.6%, diaspora 75.4%). More than half (56.9%) of the locals were not married, and 59.7%
243 from the diaspora were married. Many locals had a bachelors' degree (56.9%), and most
244 diaspora participants were postgraduate degree holders (53.3%). Most respondents from both
245 groups were employed /self-employed were predominantly non-healthcare workers and were
246 of the Christian faith. More than 80% of locals and above 90% of those in the diaspora had
247 been previously vaccinated for one or two other conditions. More than two-thirds of the
248 respondents indicated that they have never smoked. The proportion of respondents with
249 preexisting conditions was high among locals (84.6%) and diaspora (69.5%).

250 **Table 1: Characteristics (n=2545) of the study participants living in (Local) and outside**
251 **of Africa (Diaspora).**

252

| Variables | Local 2391 (93.9%) | Diaspora 154 (6.1) |
|------------------------------|-----------------------|-----------------------|
| Age group (years) | | |
| 18 – 28 | 898 (38.7) | 23 (14.9) |
| 29 – 38 | 677 (29.1) | 41 (26.6) |
| 39 – 48 | 450 (19.4) | 46 (29.9) |
| 49 + | 297 (12.8) | 44 (28.6) |
| Sex | | |
| Males | 1,264 (52.9) | 112 (72.7) |
| Females | 1,127 (47.1) | 42 (27.7) |
| SSA region of origin* | | |
| West Africa | 1,330 (55.6) | 107 (75.4) |
| East Africa | 116 (4.9) | 6 (4.2) |
| Central Africa | 288 (12.1) | 24 (16.9) |

| | | |
|---|--------------|------------|
| Southern Africa | 657 (27.5) | 5 (3.5) |
| Marital status | | |
| Married | 1,030 (43.1) | 92 (59.7) |
| Not married ‡ | 1,361 (56.9) | 62 (40.3) |
| Highest level of education | | |
| Postgraduate degree (Masters/PhD) | 668 (27.9) | 82 (53.3) |
| Bachelor's degree | 1,237 (51.7) | 61 (39.6) |
| Secondary/High School | 436 (18.2) | 9 (5.8) |
| Primary or Less | 50 (2.1) | 2 (1.3) |
| Employment status | | |
| Employed/Self employed | 1,733 (72.5) | 139 (90.3) |
| Unemployed/Retired | 658 (27.5) | 15 (9.7) |
| Religion | | |
| Christianity | 2,140 (89.5) | 138 (89.6) |
| Others | 251 (10.5) | 16 (10.4) |
| Occupation | | |
| Non-Healthcare | 1,658 (69.3) | 95 (61.7) |
| Healthcare | 733 (30.7) | 59 (38.3) |
| Previous vaccination for any condition | | |
| No | 430 (18.0) | 15 (9.7) |
| Yes | 1,961 (82.0) | 139 (90.3) |
| Smoking Status | | |
| Ex-smoker | 142 (5.9) | 18 (11.7) |
| Current smoker | 168 (7.0) | 8(5.2) |
| Non smoker | 2,081 (87.0) | 128 (83.1) |
| Risk factors: Any pre-existing condition[§] | | |
| No | 2,022 (84.6) | 107 (69.5) |
| Yes | 369 (15.4) | 47 (30.5) |

253 *Data presented as frequencies (percentages)*

254 **SSA; Sub-Saharan Africa, † includes single, divorced, and widowed*

255 *§includes the presence of any of the following conditions: cancer, diabetes, hypertension, asthma, kidney*

256 *disease, any heart condition, sickle cell anemia*

257

258 **Prevalence of uptake, resistance and hesitancy towards COVID-** 259 **19 vaccine in SSA**

260 Figure 1 presents the prevalence of vaccine uptake, resistance and hesitancy in both

261 locals and those in the diaspora. The prevalence of COVID-19 vaccine uptake respondents

262 was almost twice higher among the diaspora (25.3%) than among the locals (14.2%).

263 Resistance to the COVID-19 vaccine was more common among the locals (68.1%) than those

264 in the diaspora (55.2%). Hesitancy to COVID-19 vaccine was almost the same for both locals

265 and resident in the diaspora(See Figure 1).

266

267 **Fig I:** Prevalence and 95% confidence intervals of vaccine uptake, resistance and hesitancy
268 among SSAs living in (within) and outside of Africa (diaspora).

269

270 **Distribution of vaccine uptake, resistance and hesitancy among** 271 **local and diaspora residents**

272 Table 2 shows the variations in the distribution of vaccine uptake, resistance and
273 hesitancy across the demographic variables as well as their mean scores for knowledge,
274 attitude and perception of risk of infection. Those aged between 39 – 48 years had the highest
275 proportion of locals that were resistant to the vaccine (70.0%) while among those in the
276 diaspora, the 18 – 28 years' age range had the highest proportion (73.9%). More males
277 (70.2%) than females (65.7%) were resistant to taking the vaccine among the locals, whereas
278 there was a preponderance of resistant females in the diaspora group (64.3%).

279 COVID-19 vaccine uptake was highest among Central African residents (20.1%) who
280 lived locally but was highest among West Africans (29.9%) in the diaspora. The uptake of
281 COVID-19 vaccine had the highest proportion among those with primary/less education [19
282 (38%)] while among those in the diaspora, uptake was highest in those having a Master's
283 degree and higher [22 (26.8%)]. Resistance was substantial in those with Master's and higher
284 degree respondents (70.7% for locals and 51.2% for those in the diaspora). For both
285 healthcare and non-healthcare workers in both groups, the greatest proportions were resistant
286 to taking the vaccine. The proportion of uptake, hesitancy and resistance towards COVID-19
287 vaccines varied with the employment status of the respondents, though the unemployed had
288 the highest proportions of vaccine resistance in both groups (72.6% for locals and 60.0% for the
289 diaspora). Christians represented the higher number of those who said they were hesitant to
290 take the vaccine (18.6%) as compared with non-Christians in the diaspora (31.3%). Those
291 who were ex-smokers had the highest proportion of those who were resistant among both the

292 locals (69.0%) and those in the diaspora (72.2%). The uptake of the vaccine was also higher
 293 among those with pre-existing conditions in both local and diaspora respondents.

294 Higher mean scores for attitude and perception were observed among the COVID-19
 295 vaccine uptake respondents for the local residents, while the mean knowledge score was
 296 highest for the hesitant group. Among the diasporas, the mean knowledge and perception
 297 scores were similarly highest in uptake respondents, but a higher score for attitude was
 298 observed in the hesitancy respondents (Table 2).

299 **Table 2. Prevalence of vaccine uptake, hesitancy and resistance among SSAs living in**
 300 **(local) and outside Africa (diaspora).**

301

| Variable | LOCAL | | | DIASPORA | | |
|-----------------------------------|-------------------|-----------------------|---------------------|------------------|---------------------|--------------------|
| | Uptake n = 340 | Resistant n = 1627 | Hesitant n = 424 | Uptake n = 39 | Resistant n = 85 | Hesitant n = 30 |
| Age in years | | | | | | |
| 18 – 28 | 127 (14.1) | 621 (69.2) | 150 (16.7) | 2 (8.7) | 17 (73.9) | 4 (17.0) |
| 29 – 38 | 101 (14.9) | 435 (64.3) | 141 (20.8) | 3 (7.3) | 25 (61.0) | 13 (31.0) |
| 39 – 48 | 61 (13.6) | 315 (70.0) | 74 (16.4) | 18 (39.1) | 20 (43.5) | 8 (17.0) |
| 49+ | 33 (11.1) | 205 (69.0) | 59 (19.9) | 16 (36.4) | 23 (52.3) | 5 (11.0) |
| Sex | | | | | | |
| Males | 159 (12.6) | 887 (70.2) | 218 (17.3) | 32 (28.6) | 58 (51.8) | 22 (19.6) |
| Females | 181 (16.1) | 740 (65.7) | 206 (18.3) | 7 (16.7) | 27 (64.3) | 8 (19.1) |
| Region | | | | | | |
| West Africa | 205 (15.4) | 897 (67.4) | 228 (17.1) | 32 (29.9) | 54 (50.5) | 21 (19.6) |
| East Africa | 6 (5.2) | 80 (69.0) | 30 (25.9) | 0 (0.0) | 3 (50.0) | 3 (50.0) |
| Central Africa | 58 (20.1) | 186 (64.6) | 44 (15.3) | 6 (25.0) | 16 (66.7) | 2 (8.3) |
| Southern Africa | 71 (10.8) | 464 (70.6) | 122 (18.6) | 0 (0.0) | 4 (80.0) | 1 (20.0) |
| Level of education | | | | | | |
| Master’s degree and higher | 68 (10.2) | 472 (70.7) | 128 (19.2) | 22 (26.8) | 42 (51.2) | 18 (22.0) |
| Bachelor’s degree | 204 (16.5) | 815 (65.9) | 218 (17.6) | 14 (23.0) | 38 (62.3) | 9 (14.8) |
| Secondary/high school | 49 (11.2) | 311 (71.3) | 76 (17.4) | 3 (33.3) | 4 (44.4) | 2 (22.2) |
| Primary/no school | 19 (38.0) | 29 (58.0) | 2 (4.0) | 0 (0.0) | 1 (50.0) | 1 (50.0) |
| Occupation | | | | | | |
| Non-healthcare | 157 (9.0) | 1,188 (71.2) | 313 (18.9) | 17 (17.9) | 61 (64.2) | 17 (17.9) |
| Healthcare | 183 (25.0) | 439 (59.9) | 111 (15.1) | 22 (37.3) | 24 (40.7) | 13 (19.5) |
| Working status | | | | | | |
| Employed | 262 (15.1) | 1,149 (66.3) | 322 (18.5) | 38 (27.3) | 76 (54.7) | 25 (18.0) |
| Unemployed | 78 (11.9) | 478 (72.6) | 102 (15.5) | 1 (6.7) | 9 (60.0) | 5 (33.3) |
| Marital/family status | | | | | | |
| Married | 126 (12.2) | 719 (69.8) | 185 (18.0) | 29 (31.5) | 47 (51.1) | 16 (17.4) |
| Not married † | 214 (15.7) | 908 (66.7) | 239 (17.6) | 10 (16.1) | 38 (61.3) | 14 (22.6) |
| Religion | | | | | | |
| Christians | 304 (14.2) | 1,439 (67.2) | 397 (18.6) | 35 (25.4) | 78 (56.5) | 25 (18.1) |
| Others | 36 (14.3) | 188 (74.9) | 27 (10.8) | 4 (25.0) | 7 (43.8) | 5 (31.3) |
| Smoking status | | | | | | |
| Ex-smoker | 21 (14.8) | 98 (69.0) | 23 (16.2) | 4 (22.2) | 13 (72.2) | 1 (5.6) |

| | | | | | | |
|---|------------|--------------|------------|------------|------------|------------|
| Current smoker | 20 (11.9) | 113 (67.3) | 35 (20.8) | 1 (12.5) | 5 (62.5) | 2 (25.0) |
| Non-smoker | 299 (14.4) | 1,627 (68.1) | 424 (17.7) | 34 (26.6) | 67 (52.3) | 27 (21.1) |
| Have you been vaccinated for any condition | | | | | | |
| No | 30 (7.0) | 326 (75.8) | 74 (17.2) | 3 (20.0) | 9 (60.0) | 3 (20.0) |
| Yes | 310 (14.2) | 1,301 (66.3) | 350 (17.9) | 36 (25.9) | 76 (54.7) | 27 (19.4) |
| Any pre-existing conditions[§] | | | | | | |
| No | 280 (13.9) | 1,383 (68.4) | 359 (17.6) | 23 (21.5) | 61 (57.0) | 23 (21.5) |
| Yes | 60 (16.3) | 244 (66.1) | 65 (17.6) | 16 (34.0) | 24 (51.1) | 7 (14.9) |
| Knowledge* | 18.7 ± 4.9 | 18.5 ± 6.3 | 19.6 ± 3.6 | 22.7 ± 3.4 | 18.9 ± 6.0 | 20.5 ± 3.8 |
| Attitude* | 1.2 ± 2.2 | 0.9 ± 2.1 | 1.0 ± 2.0 | 0.7 ± 1.9 | 0.7 ± 1.8 | 1.3 ± 2.2 |
| Perception* | 6.7 ± 2.7 | 5.6 ± 3.1 | 5.8 ± 2.3 | 7.2 ± 2.4 | 5.3 ± 3.1 | 5.9 ± 2.9 |

302 *Data presented in frequencies (percentages). *Data presented as mean ± standard deviation.*
 303 † includes single, divorced and widowed. §includes the presence of any of the following conditions: cancer,
 304 diabetes, hypertension, asthma, kidney disease, any heart condition, sickle cell anemia.
 305
 306

307 **Unadjusted analysis of factors associated with COVID-19 vaccine** 308 **uptake, resistance and hesitancy in SSA**

309 Table 3 shows the unadjusted relative risk of factors associated with resistance and
 310 hesitancy towards COVID-19 vaccination among SSA respondents living locally and in the
 311 diaspora. Among the local residents, female sex was associated with the COVID-19 vaccine
 312 resistance [RR=0.73, 95% CI; 0.58 – 0.93]. East and Southern Africa local residents were
 313 significantly associated with COVID-19 vaccine resistance [RR=3.05, 95% CI; 1.31 - 7.08
 314 and RR=1.49, 95% CI; 1.12 - 2.00 respectively] and hesitancy [RR=4.50, 95% CI; 1.83 -
 315 11.02 and RR=1.54, 95% CI; 1.09 - 2.19 respectively]. Having primary or less education was
 316 also shown to be significantly associated with COVID-19 vaccine resistance [RR=0.22, 95%
 317 CI; 0.12 – 0.41] and hesitancy [RR=0.06, 95% CI; 0.01 – 0.25] among local residents.
 318 Unemployment was significantly associated with higher risk
 319 of vaccine resistance [RR=1.40, 95% CI; 1.06 – 1.84] among local residents. Being
 320 unmarried [RR=0.74, 95% CI; 0.58 – 0.95], and having a history of vaccination for other
 321 conditions were associated with lower risk of vaccine resistance [RR=0.39, 95% CI; 0.26 –
 322 0.57] among locals. Also, those with high risk perception scores were significantly less likely

323 to resist [RR=0.88, 95% CI; 0.84 - 0.92] or be hesitant [RR=0.90, 95% CI; 0.85 - 0.94] to the
 324 COVID-19 vaccines.

325 For those in diaspora, older age (>38years) [RR=0.13, 95% CI; 0.03 - 0.65], working
 326 in healthcare sector [RR=0.32, 95% CI; 0.25 – 0.40], having a more knowledge [0.82, 95%
 327 CI; 0.73 - 0.91] and better perception scores [RR=0.77, 95% CI; 0.66 – 0.90], were
 328 associated with lower risk of COVID-19 vaccine resistance, while not being married
 329 [RR=0.74, 95% CI; 0.58 – 0.95] had a higher risk of being resistant.

330

331 **Table 3. Relative risk (RR) for factors associated with COVID-19 vaccine uptake,**
 332 **hesitancy and resistance among SSA locals and diasporas. The base reference was**
 333 **COVID-19 vaccine uptake for all variables.**

334

| Variable | LOCAL | | DIASPORA | |
|------------------------------|-------------------------|------------------------|-------------------------|------------------------|
| | Resistant RR (95%CI) | Hesitant RR (95%CI) | Resistant RR (95%CI) | Hesitant RR (95%CI) |
| Age in years | | | | |
| 18 – 28 | 1.00 | 1.00 | 1.00 | 1.00 |
| 29 – 38 | 0.88 (0.66 - 1.18) | 1.18 (0.83 - 1.67) | 0.98 (0.15 - 6.50) | 2.17 (0.26 - 17.89) |
| 39 – 48 | 1.06 (0.76 - 1.47) | 1.03 (0.68 - 1.55) | 0.13 (0.03 - 0.65) | 0.22 (0.03 - 1.47) |
| 49+ | 1.27 (0.84 - 1.92) | 1.51 (0.93 - 2.46) | 0.17 (0.03 - 0.84) | 0.16 (0.02 - 1.12) |
| Sex | | | | |
| Males | 1.00 | 1.00 | 1.00 | 1.00 |
| Females | 0.73 (0.58 - 0.93) | 0.83 (0.62 - 1.10) | 2.13 (0.83 - 5.43) | 1.66 (0.53 - 5.25) |
| Region | | | | |
| West Africa | 1.00 | 1.00 | 1.00 | 1.00 |
| East Africa | 3.05 (1.31 - 7.08) | 4.50 (1.83 - 11.02) | - | - |
| Central Africa | 0.73 (0.53 - 1.02) | 0.68 (0.44 - 1.05) | 1.58 (0.56 - 4.45) | 0.51 (0.09 - 2.76) |
| Southern Africa | 1.49 (1.12 - 2.00) | 1.54 (1.09 - 2.19) | - | - |
| Level of education | | | | |
| Master's degree and more | 1.00 | 1.00 | 1.00 | 1.00 |
| Bachelor's degree | 0.58 (0.43 - 0.77) | 0.57 (0.40 - 0.81) | 1.42 (0.64 - 3.17) | 0.79 (0.28 - 2.23) |
| Secondary/High School | 0.91 (0.62 - 1.36) | 0.82 (0.52 - 1.31) | 0.70 (0.14 - 3.40) | 0.81 (0.12 - 5.42) |
| Primary/Less | 0.22 (0.12 - 0.41) | 0.06 (0.01 - 0.25) | - | - |
| Occupation | | | | |
| Non-healthcare | 1.00 | 1.00 | 1.00 | 1.00 |
| Healthcare | 0.32 (0.25 - 0.40) | 0.30 (0.22 - 0.41) | 0.30 (0.14 - 0.67) | 0.59 (0.23 - 1.54) |
| Working status | | | | |
| Employed | 1.00 | 1.00 | 1.00 | 1.00 |
| Unemployed | 1.40 (1.06 - 1.84) | 1.06 (0.76 - 1.49) | 4.0 (0.55 - 36.83) | 7.60 (0.84 - 68.97) |
| Marital/family status | | | | |
| Married | 1.00 | 1.00 | 1.00 | 1.00 |
| Not married ‡ | 0.74 (0.58 - 0.95) | 0.76 (0.57 - 1.02) | 2.34 (1.02 - 5.41) | 2.54 (0.92 - 7.00) |
| Religion | | | | |
| Christians | 1.00 | 1.00 | 1.00 | 1.00 |
| Others | 1.10 (0.76 - 1.61) | 0.57 (0.34 - 0.97) | 0.79 (0.22 - 2.86) | 1.75 (0.43 - 7.18) |

| | | | | |
|---|--------------------|--------------------|---------------------|---------------------|
| Smoking status | | | | |
| Ex-smoker | 1.00 | 1.00 | 1.00 | 1.00 |
| Current smoker | 1.21 (0.62 - 2.36) | 1.60 (0.71 - 3.58) | 1.54 (0.14 - 17.33) | 8.0 (0.31 - 206.37) |
| Non-smoker | 1.01 (0.62 - 1.65) | 1.12 (0.61 - 2.06) | 0.61 (0.18 - 2.00) | 3.18 (0.34 - 30.10) |
| Have you been vaccinated for any condition | | | | |
| No | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 0.39 (0.26 - 0.57) | 0.46 (0.29 - 0.72) | 0.70 (0.18 - 2.76) | 0.75 (0.14 - 4.01) |
| Any pre-existing conditions[§] | | | | |
| No | 1.00 | 1.00 | 1.00 | 1.00 |
| Yes | 0.82 (0.60 - 1.12) | 0.84 (0.58 - 1.24) | 0.57 (0.26 - 1.25) | 0.44 (0.15 - 1.26) |
| Knowledge | 0.99 (0.97 - 1.01) | 1.03 (1.01 - 1.06) | 0.82 (0.73 - 0.91) | 0.87 (0.77 - 0.98) |
| Attitude | 0.96 (0.91 - 1.01) | 0.96 (0.90 - 1.03) | 0.99 (0.80 - 1.24) | 1.15 (0.90 - 1.46) |
| Perception | 0.88 (0.84 - 0.92) | 0.90 (0.85 - 0.94) | 0.77 (0.66 - 0.90) | 0.84 (0.70 - 1.01) |

335 If 95% confidence intervals (CI) around RRs that lies between 1.00 indicate not statistically significant. All comparisons were made against
 336 vaccinated pregnant women (RR=1.0).

337 ‡ includes single, divorced, and widowed.

338 §includes the presence of any of the following conditions: cancer, diabetes, hypertension, asthma, kidney
 339 disease, any heart condition, sickle cell anemia

340

341 **Adjusted analysis of factors associated with COVID-19 vaccine** 342 **uptake, resistance and hesitancy in SSA**

343 Table 4 presents the associated factors of COVID-19 vaccine resistance and hesitancy
 344 in this study. After controlling for potential confounders in the local resident group, East
 345 African respondents were more likely to be resistant [ARR= 3.33, 95% CI: 1.40 - 7.94] and
 346 hesitant [ARR= 4.64, 95% CI; 1.84 - 11.70] towards receiving COVID-19 vaccines while
 347 Central African respondents were less likely to be resistant [ARR= 0.46, 95% CI; 0.32 - 0.68]
 348 or hesitant [ARR= 0.44, 95%CI: 0.27 - 0.72] towards the vaccines. Having a bachelor's
 349 degree [ARR= 0.54, 95% CI; 0.38 - 0.76] or lower, being a health care worker [ARR= 0.24,
 350 95% CI; 0.18 - 0.32], being previously vaccinated for any condition [ARR= 0.45, 95% CI;
 351 0.30 - 0.69], and having a lower risk perception score [ARR= 0.86, 95% CI; 0.82 - 0.90]
 352 were associated with reduced risk of being resistant towards the COVID-19 vaccines among
 353 local residents in SSA. Among those in the diaspora, respondents who were aged 49 years
 354 and older [ARR= 0.17, 95% CI; 0.03 - 0.95], those who work in healthcare sectors [ARR=

355 0.25, 95% CI; 0.10 - 0.62], as well as those with lower knowledge scores [ARR= 0.82, 95%
356 CI; 0.73 – 0.91] were less likely to resist taking the COVID-19 vaccines.

357 **Table 4: Adjusted Relative Risk (ARR) for factors associated with vaccine hesitancy**
358 **among SSA residents living in (Locals) and outside of Africa (Diaspora). The base**
359 **reference was COVID-19 vaccine uptake for all variables.**
360

| Variable | Local | | Diaspora | |
|------------------------------|---------------------|---------------------|---------------------|--------------------|
| | Resistant | Hesitant | Resistant | Hesitant |
| | ARR (95%CI) | ARR (95%CI) | ARR (95%CI) | ARR (95% CI) |
| 18 – 28 years | 1.00 | 1.00 | 1.00 | 1.00 |
| 29 – 38 years | 1.32 (0.94 - 1.85) | 1.89 (1.26 - 2.84) | 1.35 (0.18 – 10.07) | 2.6 (0.30 – 23.17) |
| 39 – 48 years | 1.28 (0.867 - 1.89) | 1.29 (0.80 - 2.07) | 0.21 (0.04 – 1.17) | 0.29 (0.04 – 2.08) |
| 49 + years | 1.39 (0.86 - 2.23) | 1.74 (1.00 - 3.05) | 0.17 (0.03 – 0.95) | 0.15 (0.02 – 1.16) |
| West Africa | 1.00 | 1.00 | - | - |
| East Africa | 3.33 (1.40 - 7.94) | 4.64 (1.84 - 11.70) | - | - |
| Central Africa | 0.46 (0.32 - 0.68) | 0.44 (0.27 - 0.72) | - | - |
| Southern Africa | 1.32 (0.94 - 1.84) | 1.39 (0.94 - 2.06) | - | - |
| Master’s & above | 1.00 | 1.00 | - | - |
| Bachelor’s degree | 0.54 (0.38 - 0.76) | 0.60 (0.40 - 0.90) | - | - |
| Secondary/ high School | 0.52 (0.31 - 0.87) | 0.56 (0.31 - 1.02) | - | - |
| Primary & Less | 0.15 (0.07 - 0.32) | 0.05 (0.01 - 0.24) | - | - |
| Non-health care | 1.00 | 1.00 | 1.00 | 1.00 |
| Health care | 0.24 (0.18 - 0.32) | 0.19 (0.13 - 0.27) | 0.25 (0.10 - 0.62) | 0.46 (0.16 - 1.35) |
| Christians | 1.00 | 1.00 | - | - |
| Others | 0.96 (0.64 - 1.46) | 0.50 (0.29 - 0.86) | - | - |
| Vaccinated for any condition | 0.45 (0.30 - 0.69) | 0.48 (0.29 - 0.77) | - | - |
| Knowledge | 1.02 (1.00 – 1.05) | 1.07 (1.04 – 1.11) | 0.82 (0.73 – 0.91) | 0.88 (0.77 – 0.99) |
| Perception | 0.86 (0.82 – 0.90) | 0.85 (0.80 – 0.90) | - | - |

361 If 95% confidence intervals (CI) around RRs that lies between 1.00 indicate not statistically significant. All comparisons were made against
362 vaccinated pregnant women (RR=1.0).
363

364 Regarding COVID-19 vaccine hesitancy among local residents in SSA, the significant
365 factors included East and Central African origin, aged between 29 – 38 years, being a health
366 care worker, having a bachelor’s degree or less, non-Christians, having been previously
367 vaccinated for other conditions, higher knowledge and lower perception scores. While for
368 those in diaspora being a health care worker [ARR= 0.46, 95% CI; 0.16 - 1.35] and having
369 lower knowledge scores [ARR= 0.88, 95% CI; 0.77 – 0.99] were the factors that were
370 significant for being hesitant.

371

372 **Discussion**

373 The purpose of this study was to compare the uptake, resistance and hesitancy of the
374 COVID-19 vaccine between the local residents and diaspora dwellers in SSA region of the
375 African continent. Uptake of the COVID-19 vaccine was found to be twice as high among
376 residents in the diaspora compared to local SSA residents. The WHO and Centers for Disease
377 Control and Prevention (CDC) have suggested that the low vaccination rates in low-and-
378 middle-income countries is in part, due to inequitable distribution of vaccines. Accessibility
379 to vaccines may have played a role in the low uptake rates in our study. At the time of the
380 study, half of the 52 African countries that had received vaccines had only vaccinated up to
381 2% of their population at the time of this study, and 15 countries had vaccinated up to
382 10%.[42] However, majority of those residing in Africa and the diaspora were either resistant
383 or hesitant to get vaccinated. This finding is different from that reported in a previous study
384 [43] where a higher proportion of African residents and those in the diaspora were willing to
385 accept the vaccine when offered. A survey conducted by CDC Africa prior to the introduction
386 of vaccines on the continent found that the willingness to take the vaccine in 15 African
387 countries ranged from 59% to 93%,[44] which was in contrast with our findings of greater
388 resistance towards COVID-19 vaccination. Studies conducted in the US and UK showed that
389 Africans/Blacks were 13 times more likely to be hesitant than Whites [45-46] which is similar
390 to the high proportions of SSA in diaspora who were either hesitant or resistant to taking
391 COVID-19 vaccines.

392 Socio-demographic characteristics have been shown to play significant roles in
393 vaccine hesitancy and resistance.[46] In this study, age, region of origin, educational level,
394 occupation and religion were significantly associated with either vaccine hesitancy or
395 resistance among local and diaspora residents. Younger age groups among the local residents

396 were almost twice likely to be hesitant and older age groups were less likely to be resistant to
397 vaccines. This finding is consistent with other previous studies,[32,37,46-47] and may also be
398 related to the fact that COVID-19 is more likely to present in the severe form among older
399 age groups, making them more likely to accept the vaccine for their protection.

400 Local East African respondents were three times more likely to resist and almost five
401 times more likely to be hesitant than West Africans. This may be due to misinformation about
402 COVID-19 [48] and its vaccines [49] which was reported to be more common in East African
403 countries such as Tanzania. The results showed that the least educated respondents were less
404 likely to be resistant or hesitant. This may be as a result of not comprehending the scientific
405 arguments being advanced against the vaccines and having to make choices based on past
406 experiences or the information they do understand. A recent study in the US showed a similar
407 pattern with those with lower levels of education showing less hesitancy than those with
408 higher.[49] This is contrary to the results obtained in other studies.[35-37,42-43] A statement
409 by a 61 year old on Africa news may provide an insight into the mindset of those who are less
410 educated thereby making them more likely to accept vaccination: "If in the time of our
411 mothers, in the time we were little children if these "WhatsApp doctors" had existed (people
412 who post unreliable medical information on social media) I think we would have all died
413 because our mothers who did not go to school agreed to vaccinate us against smallpox,
414 measles, polio -- all the other diseases without debate. Today, we are more educated, but
415 curiously, we refuse vaccination. This is a certain danger for our society, according to what I
416 have read here and there. The Congo is being blacklisted because we risk many deaths if we
417 don't accept vaccination".[50]

418 Both local and diaspora healthcare workers showed less likelihood of being either
419 resistant or hesitant as compared to non-healthcare workers in this study. Resistance and

420 hesitancy have been found among health workers though lower when compared to non-
421 healthcare workers.[50-55] However, Blacks /African health workers still show higher risk
422 than their counterparts of being resistant/hesitant irrespective of the country they are in.
423 Vaccine resistance and/or hesitancy is a hindrance to the vaccination campaign, as such,
424 health workers who should be well educated about the vaccines are likely to exert an
425 influence on others and possibly deter them from getting vaccinated. Most findings in the
426 cited papers found that the fear of side effects was usually the reason for hesitancy and
427 resistance among health workers. [51-53]

428 Among the local residents, individuals from other religions were less likely to be
429 vaccine hesitant compared to those of the Christian faith. Religion has been reported to play a
430 huge role in the life of Africans and influences their health seeking behavior.[57-58] Olagoke
431 et al. reported that some religious views have contributed to the rejection of vaccination.[59]
432 However, an intervention study conducted among American Christians,[60] showed that with
433 proper presentation of scientific facts, such negative views can be changed. Community
434 engagement with religious leaders has also been advocated as a means of addressing vaccine
435 hesitancy.[61]

436 Local residents who had been previously vaccinated for other conditions were less
437 likely to be COVID-19 vaccine resistant or hesitant. This finding emphasizes the influence of
438 past experiences which can build confidence in the efficacy of vaccines. Other studies have
439 also shown a willingness to be vaccinated among those who had previously received
440 vaccinations for other diseases such as flu, yellow fever, hepatitis.[62-63] Knowledge of
441 COVID-19 vaccine was a significant factor among both local and diaspora residents.
442 Knowledge has been shown to reduce resistance to vaccine acceptance. Africans in the
443 diaspora were less likely to be hesitant or resistant to vaccines as compared to their

444 counterparts residing in Africa. This may still be related to misinformation and the need for
445 health messages to be relayed in the languages familiar to the people. Recent studies have
446 shown a decline in those who are hesitant and this has been attributed to the availability of
447 accurate information that reduces fear and leads to making informed decisions.[64] Exposure
448 to accurate information and increased knowledge about COVID-19 vaccines may help those
449 who are hesitant to be more receptive to vaccines. Among local residents, higher perception
450 scores showed a lower odd of being either resistant or hesitant. The perception that one is
451 likely to be at risk of contracting a disease can result in people taking appropriate measures to
452 protect themselves from contracting the disease.

453 **Strengths and limitations**

454 This is the first large scale study to compare acceptance of COVID-19 vaccines
455 between sub-Saharan African local residents and those in the diaspora. The study employed
456 robust analyses to control for potential confounders to reduce the possibility of a bias. The
457 distribution of the questionnaire in both English and French languages using an internet-
458 based methodology, which was the only reliable means to disseminate information at the time
459 of this study to a wider audience. Notwithstanding these strengths, the study has some
460 limitations. For example, the study did not explore concerns about vaccine safety which may
461 be an important determinant of vaccine hesitancy. The cross-sectional nature of the study
462 means that causation cannot be determined. The survey was distributed electronically using
463 social media platforms and emails, and this may have inadvertently excluded some potential
464 participants whose opinions may have differed, such as those without internet access and
465 people living in rural areas, where internet penetration remains relatively low.[65] The survey
466 was presented in English and French and thus inadvertently excluding some of the
467 Portuguese or Arabic-speaking SSA countries from participating. Although the study showed

468 satisfactory internal validity, its generalization or transferability to all SSA countries may be
469 limited.

470 **Conclusion**

471 The study showed that Africans residing both locally and in diaspora are mostly either
472 resistant or hesitant to the COVID-19 vaccines. Factors that influenced resistance and
473 hesitancy among local residents included younger age, being from East and Central Africa,
474 lower levels of education, history of previous vaccinations, being a health care worker,
475 knowledge and perceptions of COVID-19 vaccine. For Africans in the diaspora, being
476 hesitant or resistant to COVID-19 vaccines are influenced by older age, being a health care
477 worker and having adequate knowledge of vaccines. Appropriate interventions such as public
478 health messaging are required to enhance COVID-19 uptake to achieve sufficient vaccine
479 coverage.

480 **Acknowledgement:** None to acknowledge.
481

482 **References**

- 483
- 484 1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic
485 in history. *Biomed J.* 2020 Aug; 43(4):328-33. doi: 10.1016/j.bj.2020.04.007. Epub
486 2020 May 5. PubMed PMID: 32387617; PubMed Central PMCID: PMC7199674.
 - 487 2. Seong H, Hyun HJ, Yun JG, Noh JY, Cheong HJ, Kim WJ et al. Comparison of the
488 second and third waves of the COVID-19 pandemic in South Korea: Importance of
489 early public health intervention. *Int J Infect Dis.* 2021 Mar; 104:742-5. doi:
490 10.1016/j.ijid.2021.02.004. Epub 2021 Feb 5. PubMed PMID: 33556610; PubMed
491 Central PMCID: PMC7863747.

- 492 3. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M et al. The first
493 and second waves of the COVID-19 pandemic in Africa: a cross-sectional study.
494 Lancet. 2021 Apr 3; 397(10281):1265-75. doi: 10.1016/S0140-6736(21)00632-2.
495 Epub 2021 Mar 24. PubMed PMID: 33773118; PubMed Central PMCID:
496 PMC8046510.
- 497 4. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics
498 and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron
499 wave compared with previous waves. JAMA. 2022 Feb 8; 327(6):583-4. doi:
500 10.1001/jama.2021.24868. PubMed PMID: 34967859; PubMed Central PMCID:
501 PMC8719272.
- 502 5. Grabowski F, Kochończyk M, Lipniacki T. The spread of SARS-CoV-2 variant
503 Omicron with a doubling time of 2.0–3.3 days can be explained by immune evasion.
504 Viruses. 2022; 14(2):294. <https://doi.org/10.3390/v14020294>.
- 505 6. Brandal LT., MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U et al. Outbreak
506 caused by the SARS-CoV-2 Omicron variant in Norway, November to December
507 2021. Euro Surveill. 2021; 26 (50). pii=2101147. [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101147)
508 [7917.ES.2021.26.50.2101147](https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101147).
- 509 7. Helmsdal G, Hansen OK, Møller LF, Christiansen DH, Petersen MS, Kristiansen MF.
510 Omicron outbreak at a private gathering in the Faroe Islands, infecting 21 of 33 triple-
511 vaccinated healthcare workers. Clin Infect Dis. 2022 Feb 3:ciac089. doi:
512 10.1093/cid/ciac089. Epub ahead of print. PubMed PMID: 35134167.
- 513 8. Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK et al.
514 Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern
515 and its global perspective. J Med Virol. 2022 Apr; 94(4):1738-44. doi:
516 10.1002/jmv.27524. Epub 2022 Jan 11. Pub Med PMID: 34905235.

- 517 9. Odusanya OO, Odugbemi BA, Odugbemi TO, Ajisegiri WS. COVID-19: A review of
518 the effectiveness of non-pharmacological interventions. Niger Postgrad Med J. 2020;
519 27(4)261-7.
- 520 10. Gokmen Y, Baskici C, Ercil Y. Effects of non-pharmaceutical interventions against
521 COVID-19: A cross-country analysis. Int J Health Plann Manage. 2021 Jul;
522 36(4):1178-88. doi: 10.1002/hpm.3164. Epub 2021 Apr 5. PubMed PMID: 33819370;
523 PubMed Central PMCID: PMC8251211.
- 524 11. Schuchat A. Human vaccines and their importance to public health. Procedia
525 Vaccinol 2011; 5: 120-6.
- 526 12. World Health Organization [Internet]. Draft landscape and tracker of COVID-19
527 candidate vaccines; c2020 [cited 2022 Jan 23]. Available from:
528 [https://www.who.int/docs/default-source/a-future-for-children/novel-](https://www.who.int/docs/default-source/a-future-for-children/novel-coronavirus_landscape_covid-19.pdf?sfvrsn=4d8bd201_1)
529 [coronavirus_landscape_covid-19.pdf?sfvrsn=4d8bd201_1](https://www.who.int/docs/default-source/a-future-for-children/novel-coronavirus_landscape_covid-19.pdf?sfvrsn=4d8bd201_1).
- 530 13. World Health Organization [Internet]. Guidance document: Status of COVID-19
531 Vaccines within WHO EUL/PQ evaluation process; c2022 [cited 2021 May 20].
532 Available from:
533 https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02
534 [March2022.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02).
- 535 14. National Research Council (US) Division of Health Promotion and Disease
536 Prevention. Vaccine Supply and Innovation. Washington (DC): National Academies
537 Press (US); c1985 [cited 2021 may 21] 3, Vaccine Availability: Concerns, Barriers,
538 and Impediments. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK216807/>.
- 539 15. Valckx S, Crèvecoeur J, Verelst F, Vranckx M, Hendrickx G, Hens N et al. Individual
540 factors influencing COVID-19 vaccine acceptance in between and during pandemic
541 waves (July-December 2020). Vaccine. 2022 Jan 3; 40(1):151-61. doi:

- 542 10.1016/j.vaccine.2021.10.073. Epub 2021 Dec 1. Pubmed PMID: 34863621;
543 PubMed Central PMCID: PMC8634074..
- 544 16. Mustapha M, Lawal BK, Sha'aban A, Jatau AI, Wada AS, Bala AA et al. Factors
545 associated with acceptance of COVID-19 vaccine among University health sciences
546 students in Northwest Nigeria. PLoS One. 2021 Nov 29;16(11):e0260672. doi:
547 10.1371/journal.pone.0260672. PubMed PMID: 34843594; PubMed Central PMCID:
548 PMC8629299.
- 549 17. Kamal AHM, Sarkar T, Khan MM, Roy SK, Khan SH, Hasan SMM et al. Factors
550 affecting willingness to receive COVID-19 vaccine among adults: a cross-sectional
551 study in Bangladesh. Journal of Health Management.2021 Oct. doi:
552 10.1177/09735984211050691.
- 553 18. Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the
554 elephant (not) in the room. Lancet Microbe. 2021 Jul; 2(7):e279-e280. doi:
555 10.1016/S2666-5247(21)00069-0. Epub 2021 Apr 20. PubMed PMID: 33899038;
556 PubMed Central PMCID: PMC8057721.
- 557 19. Cho W, Kirwin MF [Internet]. WP71: A vicious circle of corruption and mistrust in
558 institutions in sub-Saharan Africa: a micro-level analysis. Afrobarometer; c2007
559 [cited 2022 Jan 23]. Available from: [https://afrobarometer.org/publications/wp71-](https://afrobarometer.org/publications/wp71-vicious-circle-corruption-and-mistrust-institutions-sub-saharan-africa-micro-level)
560 [vicious-circle-corruption-and-mistrust-institutions-sub-saharan-africa-micro-level](https://afrobarometer.org/publications/wp71-vicious-circle-corruption-and-mistrust-institutions-sub-saharan-africa-micro-level).
- 561 20. Razai MS, Chaudhry U A R, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination
562 hesitancy BMJ. 2021; 373:n1138. doi:10.1136/BMJ.n1138.
- 563 21. World Health Organization [Internet]. Ten threats to global health in 2019; c2019
564 [cited 2022 Jan 23]. Available from: [https://www.who.int/news-room/spotlight/ten-](https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019)
565 [threats-to-global-health-in-2019](https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019).
- 566 22. Geoghegan S, O'Callaghan KP, Offit PA. Vaccine safety: myths and misinformation.

- 567 Front Microbiol. 2020 Mar 17; 11:372. doi: 10.3389/fmicb.2020.00372. PubMed
568 PMID: 32256465; PubMed Central PMCID: PMC7090020.
- 569 23. Umakanthan S, Patil S, Subramaniam N, Sharma R. COVID-19 vaccine hesitancy and
570 resistance in India explored through a population-based longitudinal survey. *Vaccines*
571 (Basel). 2021 Sep 24; 9(10):1064. doi: 10.3390/vaccines9101064. PubMed PMID:
572 34696172; PubMed Central PMCID: PMC8537475.
- 573 24. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ.
574 COVID-19 vaccination hesitancy in the United States: a rapid national assessment. *J*
575 *Community Health*. 2021 Apr; 46(2):270-7. doi: 10.1007/s10900-020-00958-x. Epub
576 2021 Jan 3. PubMed PMID: 33389421; PubMed Central PMCID: PMC7778842.
- 577 25. Kini A, Morgan R, Kuo H, Shea P, Shapiro J, Leng SX et al. Differences and
578 disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage
579 by age, sex, gender, and race. *Vaccine*. 2022 Mar 8; 40(11):1643-54. doi:
580 10.1016/j.vaccine.2021.04.013. Epub 2021 Apr 28. PubMed PMID: 33933316;
581 PubMed Central PMCID: PMC8551304.
- 582 26. Niederhauser VP, Stark M. Narrowing the gap in childhood immunization disparities.
583 *Pediatr Nurs*. 2005 Sep-Oct; 31(5):380-6. PubMed PMID: 16295153.
- 584 27. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. No populations left behind: vaccine
585 hesitancy and equitable diffusion of effective COVID-19 vaccines. *J Gen Intern Med*.
586 2021 Jul; 36(7):2130-3. doi: 10.1007/s11606-021-06698-5. Epub 2021 Mar 22.
587 PubMed PMID: 33754319; PubMed Central PMCID: PMC7985226.
- 588 28. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine
589 acceptance in the US. *EClinicalMedicine*. 2020 Sep; 26:100495. doi:
590 10.1016/j.eclinm.2020.100495. Epub 2020 Aug 12. PubMed PMID: 32838242;
591 PubMed Central PMCID: PMC7423333.

- 592 29. The ICD “Experience Africa” Program [Internet]. The African Diaspora. Introduction
593 to the African Diaspora across the World; c2021 [cited 2022 Jan 23]. Available from:
594 https://www.experience-africa.de/index.php?en_the-african-diaspora.
- 595 30. African Diaspora [Internet]. Meeting of Experts on the Definition of the African
596 Diaspora 11 – 12 April 2005 Addis Ababa, Ethiopia. Report of the meeting of experts
597 from members of States on the definition of African Diaspora; c2021 [cited 2022 Jan
598 23]. Available from: <http://www.dirco.gov.za/diaspora/definition.html>.
- 599 31. Riesen M, Konstantinoudis G, Lang P, Low N, Hatz C, Maeusezahl M et al.
600 Exploring variation in human papillomavirus vaccination uptake in Switzerland: a
601 multilevel spatial analysis of a national vaccination coverage survey. *BMJ Open*.
602 2018 May 17; 8(5):e021006. doi: 10.1136/bmjopen-2017-021006. PubMed PMID:
603 29773702; PubMed Central PMCID: PMC5961588.
- 604 32. McAuslane H, Utsi L, Wensley A, Coole L, Inequalities in maternal pertussis
605 vaccination uptake: a cross-sectional survey of maternity units, *J Public Health*. 2018
606 Mar; 40(1):121–8. doi: <https://doi.org/10.1093/pubmed/fox032>.
- 607 33. Basak P, Abir T, Al Mamun A, Zainol NR, Khanam M, Haque MR et al. A global
608 study on the correlates of Gross Domestic Product (GDP) and COVID-19 vaccine
609 distribution. *Vaccines*. 2022; 10(2):266. doi:
610 <https://doi.org/10.3390/vaccines10020266>.
- 611 34. World Health Organization [Internet]. Africa on track to control COVID-19 pandemic
612 in 2022; c2022 [cited 2022 Jan 23]. Available from:
613 <https://www.afro.who.int/news/africa-track-control-covid-19-pandemic-2022>.
- 614 35. World Health Organization Regional Office for Africa [Internet]. Risks and
615 challenges in Africa’s COVID-19 vaccine rollout; c2021 [cited 2022 Jan 23]
616 Available from: <https://www.afro.who.int/news/risks-and-challenges-africas-covid->

- 617 19-vaccine-rollout.
- 618 36. Dzinamarira T, Nachipo B, Phiri B, Musuka G. COVID-19 vaccine roll-out in South
619 Africa and Zimbabwe: urgent need to address community preparedness, fears and
620 hesitancy. *Vaccines*. 2021; 9(3):250. doi: <https://doi.org/10.3390/vaccines9030250>.
- 621 37. Abu EK, Oloruntoba R, Osuagwu UL, Bhattarai D, Miner CA, Goson PC et al. Risk
622 perception of COVID-19 among sub-Saharan Africans: a web-based comparative
623 survey of local and diaspora residents. *BMC Public Health*. 2021 Aug 18; 21(1):1562.
624 doi: [10.1186/s12889-021-11600-3](https://doi.org/10.1186/s12889-021-11600-3). PubMed PMID: 34404377; PubMed Central
625 PMCID: PMC8370831.
- 626 38. World Medical Assembly [Internet]. WMA Declaration of Helsinki - Ethical
627 Principles for Medical Research Involving Human Subjects. c2013 [cited 2022 Jan
628 23]. Available from: [https://www.wma.net/policies-post/wma-declaration-of-helsinki-
629 ethical-principles-for-medical-research-involving-human-subjects/](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/).
- 630 39. Geldsetzer P. Use of rapid online surveys to assess people's perceptions during
631 infectious disease outbreaks: a cross-sectional survey on COVID-19. *J Med Internet
632 Res*. 2020 Apr 2; 22(4):e18790. doi: [10.2196/18790](https://doi.org/10.2196/18790). Pubmed PMID: 32240094;
633 PubMed Central PMCID: PMC7124956.
- 634 40. Biasio LR, Bonaccorsi G, Lorini C, Pecorelli S. Assessing COVID-19 vaccine
635 literacy: a preliminary online survey. *Hum Vaccin Immunother*. 2021 May
636 4;17(5):1304-12. doi: [10.1080/21645515.2020.1829315](https://doi.org/10.1080/21645515.2020.1829315). Epub 2020 Oct 29. PubMed
637 PMID: 33118868; PubMed Central PMCID: PMC8078752.
- 638 41. Buzasi K. Linguistic Situation in Twenty sub-Saharan African Countries: A Survey-
639 based Approach. *Afr Stud*. 2016; 75:358–80. doi: [10.1080/00020184.2016.1193376](https://doi.org/10.1080/00020184.2016.1193376)
- 640 42. World Health Organization Regional Office for Africa [Internet]. Fifteen African
641 countries hit 10% COVID-19 vaccination goal; c2021 [cited 2022 Jan 23]. Available

- 642 from: <https://www.afro.who.int/news/fifteen-african-countries-hit-10-covid-19->
643 [vaccination-goal.](https://www.afro.who.int/news/fifteen-african-countries-hit-10-covid-19-)
- 644 43. Anjorin AA, Odetokun IA, Abioye AI, Elnadi H, Umoren MV, Damaris BF, et al.
645 Will Africans take COVID-19 vaccination? PLoS ONE. 2021; 16(12): e0260575. doi:
646 <https://doi.org/10.1371/journal.pone.0260575>.
- 647 44. Africa Centers for Disease Control and Prevention [Internet]. COVID 19 vaccine
648 perceptions: A 15 country study; c2021 [cited 2022 Jan 23]. Available from:
649 <https://africacdc.org/download/covid-19-vaccine-perceptions-a-15-country-study/>.
- 650 45. Momplaisir FM, Kuter BJ, Ghadimi F, Browne S, Nkwihoreze H, Feemster KA et al.
651 Racial/ethnic differences in COVID-19 vaccine hesitancy among health care workers
652 in 2 large academic hospitals. JAMA Netw Open. 2021 Aug 2; 4(8):e2121931. doi:
653 [10.1001/jamanetworkopen.2021.21931](https://doi.org/10.1001/jamanetworkopen.2021.21931). PubMed PMID: 34459907; PubMed Central
654 PMCID: PMC8406078.
- 655 46. Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M et al.
656 Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study.
657 Brain Behav Immun. 2021 May; 94:41-50. doi: [10.1016/j.bbi.2021.03.008](https://doi.org/10.1016/j.bbi.2021.03.008). Epub
658 2021 Mar 11. PubMed PMID: 33713824; PubMed Central PMCID: PMC7946541.
- 659 47. Lazarus JV, Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO et al. Hesitant or not?
660 The association of age, gender, and education with potential acceptance of a COVID-
661 19 vaccine: a country-level analysis. J Health Commun. 2020 Oct 2;25(10):799-807.
662 doi: [10.1080/10810730.2020.1868630](https://doi.org/10.1080/10810730.2020.1868630). PubMed PMID: 33719881.
- 663 48. Osuagwu UL, Miner CA, Bhattarai D, Mashige KP, Oloruntoba R, Abu EK et al.
664 Misinformation about COVID-19 in sub-Saharan Africa: evidence from a cross-
665 sectional survey. Health Secure. 2021 Jan-Feb;19(1):44-56. DOI:
666 [10.1089/HS.2020.0202](https://doi.org/10.1089/HS.2020.0202). PMID: 33606572.

- 667 49. King WC, Rubinstein M, Reinhart A, Mejia R. Time trends, factors associated with,
668 and reasons for COVID-19 vaccine hesitancy: A massive online survey of US adults
669 from January-May 2021. PLoS One. 2021 Dec 21; 16(12):e0260731. doi:
670 10.1371/journal.pone.0260731. PubMed PMID: 34932583; PubMed Central PMCID:
671 PMC8691631.
- 672 50. Asala K; Africanews [Internet]. DR Congo: COVID-19 vaccine hesitation amid
673 surging cases in third wave. [cited 2022 Feb 21]. Available from:
674 [https://www.africanews.com/2021/07/02/dr-congo-covid-19-vaccine-hesitation-amid-](https://www.africanews.com/2021/07/02/dr-congo-covid-19-vaccine-hesitation-amid-surging-cases-in-third-wave/)
675 [surging-cases-in-third-wave//](https://www.africanews.com/2021/07/02/dr-congo-covid-19-vaccine-hesitation-amid-surging-cases-in-third-wave/).
- 676 51. Toth-Manikowski SM, Swirsky ES, Gandhi R, Piscitello G. COVID-19 vaccination
677 hesitancy among health care workers, communication, and policy-making. Am J
678 Infect Control. 2022 Jan; 50(1):20-5. doi: 10.1016/j.ajic.2021.10.004. Epub 2021 Oct
679 13. PubMed PMID: 34653527; PubMed Central PMCID: PMC8511871.
- 680 52. Amuzie CI, Odim F, Kalu KU, Izuka M, Nwamoh U, Emma-Ukaegbu U et al.
681 COVID-19 vaccine hesitancy among healthcare workers and its socio-demographic
682 determinants in Abia State, Southeastern Nigeria: a cross-sectional study. Pan Afr
683 Med J. 2021 Sep 3; 40:10. doi: 10.11604/pamj.2021.40.10.29816. PubMed PMID:
684 34650660; PubMed Central PMCID: PMC8490164..
- 685 53. Aoun AH, Aon MH, Alshammari AZ, Moussa SA. COVID-19 vaccine hesitancy
686 among health care workers in the Middle East Region. Open Public Health J. 2021;
687 14: 352–9. doi: 10.2174/1874944502114010352.
- 688 54. Angelo AT, Alemayehu DS, Dachew AM. Health care workers intention to accept
689 COVID-19 vaccine and associated factors in southwestern Ethiopia. 2021. PLoS One.
690 2021 Sep 3; 16(9):e0257109. doi: 10.1371/journal.pone.0257109. PubMed PMID:
691 34478470; PubMed Central PMCID: PMC8415602.

- 692 55. Ashok N, Krishnamurthy K, Singh K, Rahman S, Majumder MAA. High COVID-19
693 Vaccine Hesitancy Among Healthcare Workers: Should Such a Trend Require Closer
694 Attention by Policymakers? *Cureus*. 2021 Sep 15; 13(9):e17990. doi:
695 10.7759/cureus.17990. PubMed PMID: 34667668; PubMed Central PMCID:
696 PMC8519358.
- 697 56. Algabbani F, Algabbani A. Vaccine hesitancy among healthcare providers during
698 COVID-19 pandemic. *Eur J Public Health*. 2021; 31 Suppl_7. doi:
699 <https://doi.org/10.1093/eurpub/ckab164.101>
- 700 57. Wirsiy FS, Nkfusai CN, Ako-Arrey DE, Dongmo EK, Manjong FT, Cumber SN.
701 Acceptability of COVID-19 Vaccine in Africa. *Int J MCH AIDS*. 2021; 10(1):134-8.
702 doi: 10.21106/ijma.482. Epub 2021 Apr 8. PubMed PMID: 33868778; PubMed
703 Central PMCID: PMC8039868.
- 704 58. Costa JC, Weber AM, Darmstadt GL, Abdalla S, Victora CG. Religious affiliation
705 and immunization coverage in 15 countries in Sub-Saharan Africa. *Vaccine*. 2020 Jan
706 29; 38(5):1160-9. doi: 10.1016/j.vaccine.2019.11.024. Epub 2019 Nov 30. PubMed
707 PMID: 31791811; PubMed Central PMCID: PMC6995994.
- 708 59. Olagoke AA, Olagoke OO, Hughes AM. Intention to vaccinate against the novel 2019
709 coronavirus disease: the role of health locus of control and religiosity. *J Relig Health*.
710 2021 Feb; 60(1):65-80. doi: 10.1007/s10943-020-01090-9. Epub 2020 Oct 30.
711 PubMed PMID: 33125543; PubMed Central PMCID: PMC7596314.
- 712 60. Chu J, Pink SL, Willer R. Religious identity cues increase vaccination intentions and
713 trust in medical experts among American Christians. *Proc Natl Acad Sci U S A*. 2021
714 Dec 7; 118(49):e2106481118. doi: 10.1073/pnas.2106481118. PubMed PMID:
715 34795017; PubMed Central PMCID: PMC8670469.
- 716 61. Melillo S, Fountain D, Bormet M, O'Brien CJ; MOMENTUM Country and Global

717 Leadership. Effects of faith actor engagement in the uptake and coverage of
718 immunization in low- and middle-income countries (LMICs)* Phase 1 Global
719 Landscape : Evidence Summary. c2021 [cited 2022 Jan 24]. Available from:
720 [https://usaidmomentum.org/wp-content/uploads/2021/07/Faith-Engagement-in-](https://usaidmomentum.org/wp-content/uploads/2021/07/Faith-Engagement-in-Immunization_Global-Landscape-Analysis_Evidence-Summary-Report_June-2021_Sec508comp-low.pdf)
721 [Immunization_Global-Landscape-Analysis_Evidence-Summary-Report_June-](https://usaidmomentum.org/wp-content/uploads/2021/07/Faith-Engagement-in-Immunization_Global-Landscape-Analysis_Evidence-Summary-Report_June-2021_Sec508comp-low.pdf)
722 [2021_Sec508comp-low.pdf](https://usaidmomentum.org/wp-content/uploads/2021/07/Faith-Engagement-in-Immunization_Global-Landscape-Analysis_Evidence-Summary-Report_June-2021_Sec508comp-low.pdf).

723 62. El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ.
724 Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from
725 Jordan. PLoS One. 2021 Apr 23; 16(4):e0250555. doi:
726 [10.1371/journal.pone.0250555](https://doi.org/10.1371/journal.pone.0250555). PubMed PMID: 33891660; PubMed Central PMCID:
727 [PMC8064595](https://pubmed.ncbi.nlm.nih.gov/33891660/).

728 63. Wake AD. The willingness to receive COVID-19 vaccine and its associated factors:
729 "Vaccination refusal could prolong the war of this pandemic" - a systematic review.
730 Risk Manag Healthc Policy. 2021 Jun 21; 14:2609-2623. doi:
731 [10.2147/RMHP.S311074](https://doi.org/10.2147/RMHP.S311074). PubMed PMID: 34188572; Pubmed Central PMCID:
732 [PMC8232962](https://pubmed.ncbi.nlm.nih.gov/34188572/).

733 64. Siegler AJ, Luisi N, Hall EW, Bradley H, Sanchez Z, Lopman BA et al. Trajectory of
734 COVID-19 vaccine hesitancy over time and association of initial vaccine hesitancy
735 with subsequent vaccination. JAMA Netw Open. 2021; 4(9): e2126882–e2126882.
736 doi:[10.1001/jamanetworkopen.2021.26882](https://doi.org/10.1001/jamanetworkopen.2021.26882).


737 65. Hjort, J, Poulsen, J. The arrival of fast internet and employment in Africa. American
738 Economic Review. 2019; 109(3):1032-79. doi: [10.1257/aer.20161385](https://doi.org/10.1257/aer.20161385)

739 **Supporting information**

740

741 S1 Table. Sample of the survey items used in this study

742



Figure